Advanced treatments, including biologics, have been a mainstay of treatment for moderate-to-severe disease in PsO longer than AD and disease outcomes like a minimum %BSA serve in PsO as a threshold for initiating those therapies. There are fewer reported outcomes for AD as a condition and as a result it was determined to include all[…]
While assessments like EASI and the SCORAD index are commonly used in clinical trials, they are not practical for clinical practice because they are time-consuming and were not developed and validated for routine care. The dataset is a reflection of assessments conducted in routine care.
OM1 extracts PsO subtypes (plaque, pustular, erythrodermic, guttate, seborrheic, inverse, scalp and nail) from the clinical notes and approximately a third of patients have at least one record. Subtypes are located in the Observation Table. The majority of patients have plaque psoriasis. Bodily location (e.g., scalp, abdomen, legs) is also extracted from the clinical notes[…]
These ClinROs (PASI, PGA) and PROs (DLQI) are not routinely captured in clinical care so completion rates vary. OM1’s relationships with our Dermatology Network can be leveraged to solicit these directly through OM1’s protocol-driven ClinPRO program.
We would expect to find one or more annual lab panels for patients treated with a biologic therapy or cDMARD. Expected labs may include: CBC, CMP, Hep B Panel, Hep C Ab, and Quantiferon Gold (TB).
